Form 4: Athira Pharma Director Kelly Romano Granted Stock Options as Part of Compensation Policy

Athira Pharma, Inc. Director Kelly A. Romano was granted 20,900 stock options with an exercise price of $0.3125, as disclosed in a recent SEC Form 4 filing.

Summary

• Athira Pharma, Inc. (ATHA) Director Kelly A. Romano was granted 20,900 stock options.
• The options have an exercise price of $0.3125 per share.
• The transaction date for the grant was May 30, 2025.
• The options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• The expiration date for these options is May 29, 2035.
• This grant was made pursuant to the terms of Athira Pharma's Outside Director Compensation Policy.
• Following this transaction, Kelly A. Romano beneficially owns 20,900 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects standard corporate governance and compensation practices, aligning director interests with shareholders. It is a routine disclosure with no negative surprises.

Positives

• The grant of stock options aligns the interests of Director Kelly A. Romano with those of the shareholders, as the value of the options is tied to the company's stock performance.
• This transaction is part of a standard compensation policy for outside directors, indicating adherence to established corporate governance practices.

Negatives

• No immediate negative implications are apparent from this standard insider compensation disclosure.

Risks

• Potential future dilution of existing shareholders' equity upon the exercise of these stock options, a common characteristic of equity compensation plans.

Future Outlook

The granted stock options are subject to a vesting schedule, which will occur on the earlier of May 30, 2026, or the day immediately before the next annual meeting of stockholders after May 30, 2025, indicating a future milestone for the options to become exercisable.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology and pharmaceuticals, serving as a form of long-term incentive and aligning director interests with company performance. This specific grant is consistent with typical compensation structures for outside directors in publicly traded companies.

Comparison to Industry Standards

• Not applicable for this specific insider transaction disclosure, as it details a single compensation event rather than company-wide financial or operational results that would be benchmarked against industry peers.

Corporate Governance

Related Party Transactions

• The grant of 20,900 stock options to Kelly A. Romano, a Director of Athira Pharma, Inc., constitutes a related party transaction as it involves compensation provided by the issuer to an insider.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon option exercise, but also benefit from increased alignment of director incentives with company performance.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The stock options will vest on the earlier of May 30, 2026, or the day before the next annual meeting of stockholders after May 30, 2025, at which point they will become exercisable.

Key Dates

Keywords

Athira Pharma, ATHA, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Kelly A. Romano, Biotechnology, Pharmaceuticals